Revicki D, Barker C; International Society of Technology Assessment in Health Care. Meeting.
Annu Meet Int Soc Technol Assess Health Care Int Soc Technol Assess Health Care Meet. 1998; 14: 48.
MEDTAP International, Bethesda, MD, USA.
OBJECTIVE: This study evaluated the impact of saquinavir combination therapy for human immunodeficiency virus (HIV) infection on patient quality of life. METHODS: An international randomized clinical trial was conducted to evaluate treatment with zalcitabine-zidovuldine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine. 993 HIV-infected patients with CD4 counts between 50 and 250 cells/mm3 with <16 weeks of antiretroviral therapy were randomized to: zalcitabine 0.75mg and zidovudine 200mg every 8 hours (ddC/ZDV); or saquinavir 600mg, zidovudine 200mg every 8 hours (SQV/ZDV); or saquinavir 600mg, zalcitabine 0.75mg and zidovudine 200mg every 8 hours (SQV/ddC/ZDV) for 48 weeks. Quality of life was measured using Medical Outcome Study HIV (MOS-HIV) Health Survey scale and physical and mental health summary scores. RESULTS: After 48 weeks, statistically significant differences among 3 treatments were observed for physical and mental health summary scores (p=.02). The SQV/ddC/ZDV group showed small changes in physical health summary scores, while the ddC/ZDV group showed decreases in physical health summary scores (p<.05). Six of the 10 MOS-HIV scale scores demonstrated findings consistant with physical health summary scores (all p<.05). CONCLUSIONS: Patients on SQV/ddC/ZDV therapy demonstrated no change in or slight improvements in quality of life compared with significant declines in patients on ddC/ZDV therapy.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Adult
- Anti-HIV Agents
- HIV
- HIV Infections
- HIV Protease
- HIV Protease Inhibitors
- HIV Seropositivity
- Humans
- Life
- Quality of Life
- Saquinavir
- Zalcitabine
- Zidovudine
- hsrmtgs
Other ID:
UI: 102234607
From Meeting Abstracts